A

Acarix AB
STO:ACARIX

Watchlist Manager
Acarix AB
STO:ACARIX
Watchlist
Price: 0.285 SEK
Market Cap: kr320.1m

Acarix AB
Other

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Acarix AB
Other Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other CAGR 3Y CAGR 5Y CAGR 10Y
A
Acarix AB
STO:ACARIX
Other
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Elekta AB (publ)
STO:EKTA B
Other
-kr1.4B
CAGR 3-Years
-23%
CAGR 5-Years
8%
CAGR 10-Years
N/A
CellaVision AB
STO:CEVI
Other
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Getinge AB
STO:GETI B
Other
kr3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Arjo AB (publ)
STO:ARJO B
Other
-kr71m
CAGR 3-Years
N/A
CAGR 5-Years
22%
CAGR 10-Years
N/A
S
Stille AB
STO:STIL
Other
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Acarix AB
Glance View

Market Cap
320.1m SEK
Industry
Health Care

Acarix AB is engaged in the provision of medical devices for monitoring Coronary Artery Disease. The company is headquartered in Malmo, Skane. The company went IPO on 2016-12-19. The Company’s primary product CADScor System features phonocardiography technique and algorithms. The CADScor System is fixed with a specific patch to the chest of the patient, with the recording head placed at the forth left intercostal space, and the sensor resting on the sternum. Instructions for the procedure are given on the display for the operator and audio cues guide a patient during the two-minute heart sound recording. After recording, the CAD-score is calculated, and presented on the display of the CADScor Sensor, enabling a physicians, nurses and laboratory technicians to make a rule-out diagnosis.

ACARIX Intrinsic Value
0.414 SEK
Undervaluation 31%
Intrinsic Value
Price kr0.285
A

See Also

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett